Journal Watch · Circulation · 2026
Women's Kidney Health in Focus: A Scientific Statement From the American Heart Association.
Advancing precision kidney medicine for women requires equitable access to kidney care, embedding assessment of reproductive health in chronic care, trial design with adequate power that includes both women and men, and mechanistic studies linking reproductive health to long-term cardiovascular disease and chronic kidney disease development and progression.
TL;DR
Advancing precision kidney medicine for women requires equitable access to kidney care, embedding assessment of reproductive health in chronic care, trial design with adequate power that includes both women and men, and mechanistic studies linking reproductive health to long-term cardiovascular disease and chronic kidney disease development and progression.
Key findings
- Endocrine and metabolic disorders such as polycystic ovary syndrome increase susceptibility to chronic kidney disease.
- Family planning, prepregnancy counseling, and antenatal care are essential to support reproductive health in women with chronic kidney disease.
- Because chronic kidney disease and cardiovascular disease are tightly intertwined, chronic kidney disease is also a leading contributor to cardiovascular mortality in women.
- Advancing precision kidney medicine for women requires equitable access to kidney care, embedding assessment of reproductive health in chronic care, trial design with adequate power that includes both women and men, and mechanistic studies linking reproductive health to long-term cardiovascular disease and chronic kidney disease development and progression.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
Preclinical evidence implicates a role for estrogen receptor signaling in renal physiology and pathophysiology. Women with chronic kidney disease are at increased risk for adverse pregnancy outcomes and hypertensive disorders of pregnancy, and pregnancy complications can also increase future chronic kidney disease risk. Menopause and aging accelerate chronic kidney disease progression in women as a result of declining estradiol and shifts in kidney estrogen receptor profiles.
Full abstract (original)
Background: Chronic kidney disease is a global epidemic affecting ≈10% of adults worldwide. Women have a higher prevalence of chronic kidney disease than men yet are less likely to progress to kidney failure, to initiate dialysis, or to receive a kidney transplantation, underscoring the influence of biological sex on chronic kidney disease development, progression, treatment response, and outcomes. Women may also respond differently from men to pharmacological therapies, but they remain underrepresented in clinical trials, limiting the evidence base for sex-specific kidney care.
What they did: Preclinical evidence implicates a role for estrogen receptor signaling in renal physiology and pathophysiology. Women with chronic kidney disease are at increased risk for adverse pregnancy outcomes and hypertensive disorders of pregnancy, and pregnancy complications can also increase future chronic kidney disease risk. Menopause and aging accelerate chronic kidney disease progression in women as a result of declining estradiol and shifts in kidney estrogen receptor profiles.
Results & conclusions: Endocrine and metabolic disorders such as polycystic ovary syndrome increase susceptibility to chronic kidney disease. Family planning, prepregnancy counseling, and antenatal care are essential to support reproductive health in women with chronic kidney disease. Because chronic kidney disease and cardiovascular disease are tightly intertwined, chronic kidney disease is also a leading contributor to cardiovascular mortality in women. Advancing precision kidney medicine for women requires equitable access to kidney care, embedding assessment of reproductive health in chronic care, trial design with adequate power that includes both women and men, and mechanistic studies linking reproductive health to long-term cardiovascular disease and chronic kidney disease development and progression.
Abstract © the authors / Circulation (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1161/cir.0000000000001471 · PubMed 42751780.
Why it matters for pharma & biotech
- Relevant to Pharmacology & Drug Discovery teams tracking Circulation for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
Frequently asked questions
What did this Circulation study find?
Advancing precision kidney medicine for women requires equitable access to kidney care, embedding assessment of reproductive health in chronic care, trial design with adequate power that includes both women and men, and mechanistic studies linking reproductive health to long-term cardiovascular disease and chronic kidney disease development and progression.
What type of study is this?
It is a clinical study, published in Circulation in 2026. Preclinical evidence implicates a role for estrogen receptor signaling in renal physiology and pathophysiology.
Where can I read the original paper?
The original is at the publisher via DOI 10.1161/cir.0000000000001471. PubMed ID: 42751780. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/women-s-kidney-health-in-focus-a-scientific-statement-from-the-american-001471/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides